We’re thrilled to announce that Biocytogen will be exhibiting at the 52nd Annual Meeting of the Japanese Society of Toxicology (JSOT), to be held in Okinawa, Japan, from July 2 to 4, 2025. Representatives from our Product Development Department and Asia-Pacific Business Team will be attending the conference. We will present a poster showcasing the latest research progress on our IL4/IL4RA humanized mice for toxicology studies. Please stop by our table (#100) to learn how Biocytogen’s gene-editing technologies, humanized models, and antibody discovery platforms are contributing to more sustainable and efficient drug development. We look forward to seeing you in Okinawa.

As a globally renowned provider of large-scale, ready-to-use gene-editing animal models, Biocytogen has developed 3,500 gene-edited mouse models, including over 1,100 human target knock-in (KI) mice/rats to support drug discovery. Our expertise specifically addresses complex therapeutic needs through multi-target humanized mice, which optimally serve for the in vivo efficacy study and tox study of bispecific/trispecific antibodies and combination therapies.

Event Overview 

Date: July 2-4, 2025

Venue: Okinawa Convention Center, Japan

Booth #100

Poster Title: Humanized B-hIL4/hIL4RA Mice Model for Efficacy and Toxicity Evaluation

Interested in a one-on-one meeting? Feel free to reach out to us at info@bbctg.com.cn.

For more event information, please refer to JSOT.